|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MOGAT3 |
Gene summary for MOGAT3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MOGAT3 | Gene ID | 346606 |
| Gene name | monoacylglycerol O-acyltransferase 3 | |
| Gene Alias | DC7 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q86VF5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 346606 | MOGAT3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.21e-12 | 8.04e-01 | -0.1808 |
| 346606 | MOGAT3 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.61e-08 | 4.47e-01 | -0.1954 |
| 346606 | MOGAT3 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.68e-02 | 8.22e-01 | -0.2602 |
| 346606 | MOGAT3 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.08e-04 | 8.83e-01 | -0.2196 |
| 346606 | MOGAT3 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.38e-06 | 5.60e-01 | -0.1526 |
| 346606 | MOGAT3 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.23e-08 | 4.05e-01 | -0.1464 |
| 346606 | MOGAT3 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.62e-02 | 5.61e-01 | -0.2061 |
| 346606 | MOGAT3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.94e-06 | 3.27e-01 | 0.3005 |
| 346606 | MOGAT3 | A002-C-010 | Human | Colorectum | FAP | 8.62e-04 | -1.34e-01 | 0.242 |
| 346606 | MOGAT3 | A002-C-201 | Human | Colorectum | FAP | 4.90e-02 | -1.33e-01 | 0.0324 |
| 346606 | MOGAT3 | A015-C-104 | Human | Colorectum | FAP | 1.11e-02 | -1.40e-01 | -0.1899 |
| 346606 | MOGAT3 | A002-C-116 | Human | Colorectum | FAP | 3.44e-03 | -1.34e-01 | -0.0452 |
| 346606 | MOGAT3 | Pat01-B | Human | Stomach | GC | 1.79e-29 | 5.41e-01 | 0.5754 |
| 346606 | MOGAT3 | Pat02-B | Human | Stomach | GC | 3.76e-03 | 1.34e-01 | 0.0368 |
| 346606 | MOGAT3 | Pat03-B | Human | Stomach | GC | 5.25e-15 | 3.35e-01 | 0.3693 |
| 346606 | MOGAT3 | Pat17-B | Human | Stomach | GC | 3.73e-12 | 3.48e-01 | 0.3109 |
| 346606 | MOGAT3 | SIM_1 | Human | Stomach | SIM | 3.52e-02 | 1.58e-01 | 0.3573 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006066 | Colorectum | AD | alcohol metabolic process | 106/3918 | 353/18723 | 3.02e-05 | 5.57e-04 | 106 |
| GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
| GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
| GO:00060661 | Colorectum | SER | alcohol metabolic process | 79/2897 | 353/18723 | 3.50e-04 | 5.50e-03 | 79 |
| GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
| GO:00450171 | Colorectum | SER | glycerolipid biosynthetic process | 55/2897 | 252/18723 | 4.47e-03 | 3.56e-02 | 55 |
| GO:00060662 | Colorectum | MSS | alcohol metabolic process | 92/3467 | 353/18723 | 2.57e-04 | 3.46e-03 | 92 |
| GO:00442621 | Colorectum | FAP | cellular carbohydrate metabolic process | 66/2622 | 283/18723 | 1.53e-05 | 4.01e-04 | 66 |
| GO:00060663 | Colorectum | FAP | alcohol metabolic process | 69/2622 | 353/18723 | 2.29e-03 | 1.85e-02 | 69 |
| GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
| GO:0006641 | Stomach | GC | triglyceride metabolic process | 23/1159 | 100/18723 | 3.27e-08 | 2.44e-06 | 23 |
| GO:0006639 | Stomach | GC | acylglycerol metabolic process | 24/1159 | 128/18723 | 9.59e-07 | 4.53e-05 | 24 |
| GO:0006638 | Stomach | GC | neutral lipid metabolic process | 24/1159 | 129/18723 | 1.11e-06 | 5.20e-05 | 24 |
| GO:00060665 | Stomach | GC | alcohol metabolic process | 41/1159 | 353/18723 | 7.85e-05 | 1.68e-03 | 41 |
| GO:0006071 | Stomach | GC | glycerol metabolic process | 6/1159 | 19/18723 | 7.49e-04 | 9.67e-03 | 6 |
| GO:0046460 | Stomach | GC | neutral lipid biosynthetic process | 10/1159 | 50/18723 | 8.42e-04 | 1.05e-02 | 10 |
| GO:0046463 | Stomach | GC | acylglycerol biosynthetic process | 10/1159 | 50/18723 | 8.42e-04 | 1.05e-02 | 10 |
| GO:0019432 | Stomach | GC | triglyceride biosynthetic process | 9/1159 | 42/18723 | 9.01e-04 | 1.11e-02 | 9 |
| GO:0019400 | Stomach | GC | alditol metabolic process | 6/1159 | 22/18723 | 1.75e-03 | 1.83e-02 | 6 |
| GO:00464862 | Stomach | GC | glycerolipid metabolic process | 38/1159 | 392/18723 | 4.15e-03 | 3.47e-02 | 38 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00561 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
| hsa005611 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
| hsa04975 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
| hsa005614 | Stomach | GC | Glycerolipid metabolism | 12/708 | 63/8465 | 5.36e-03 | 3.01e-02 | 2.12e-02 | 12 |
| hsa049751 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
| hsa0056111 | Stomach | GC | Glycerolipid metabolism | 12/708 | 63/8465 | 5.36e-03 | 3.01e-02 | 2.12e-02 | 12 |
| hsa049752 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
| hsa0056121 | Stomach | SIM | Glycerolipid metabolism | 9/465 | 63/8465 | 7.07e-03 | 4.30e-02 | 3.45e-02 | 9 |
| hsa049753 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
| hsa0056131 | Stomach | SIM | Glycerolipid metabolism | 9/465 | 63/8465 | 7.07e-03 | 4.30e-02 | 3.45e-02 | 9 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MOGAT3 | SNV | Missense_Mutation | c.567N>G | p.Ile189Met | p.I189M | Q86VF5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MOGAT3 | SNV | Missense_Mutation | c.386N>G | p.Thr129Ser | p.T129S | Q86VF5 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| MOGAT3 | SNV | Missense_Mutation | c.1010N>T | p.Cys337Phe | p.C337F | Q86VF5 | protein_coding | tolerated(0.48) | benign(0.04) | TCGA-E2-A14T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MOGAT3 | deletion | Frame_Shift_Del | novel | c.87delN | p.Tyr29Ter | p.Y29* | Q86VF5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| MOGAT3 | SNV | Missense_Mutation | rs201890499 | c.889G>A | p.Val297Ile | p.V297I | Q86VF5 | protein_coding | tolerated(0.14) | probably_damaging(0.959) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MOGAT3 | SNV | Missense_Mutation | novel | c.906N>A | p.His302Gln | p.H302Q | Q86VF5 | protein_coding | tolerated(0.82) | benign(0.007) | TCGA-C5-A8YT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| MOGAT3 | SNV | Missense_Mutation | rs771019638 | c.586N>A | p.Glu196Lys | p.E196K | Q86VF5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| MOGAT3 | SNV | Missense_Mutation | rs763725968 | c.898C>T | p.Arg300Cys | p.R300C | Q86VF5 | protein_coding | tolerated(0.55) | benign(0.005) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MOGAT3 | SNV | Missense_Mutation | c.830N>A | p.Ser277Tyr | p.S277Y | Q86VF5 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MOGAT3 | SNV | Missense_Mutation | rs139340331 | c.475G>A | p.Asp159Asn | p.D159N | Q86VF5 | protein_coding | deleterious(0.04) | possibly_damaging(0.617) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |